Targeted Virology Focus RetroVirox specializes exclusively in virology with a broad suite of antiviral and neutralization assays offered as fee-for-service or F.T.E. pricing. This positions them as a go-to CRO for preclinical virology testing, including cell-based infectivity, replication, and neutralization assays across multiple human viruses, appealing to biotech startups and large pharma seeking specialized virology capabilities.

Diverse Virus Portfolio The company validates and offers assays against more than a dozen viruses, including high-interest pathogens like SARS-CoV-2, influenza strains, RSV, HIV, and hemorrhagic viruses. This diversity enables cross-program support for clients developing vaccines, antibodies, or antivirals targeting multiple viral families, opening multi-project collaboration opportunities.

Preclinical Track Record RetroVirox has supported preclinical discovery for hundreds of companies and contributed to the preclinical efforts of three FDA-approved drugs. This established track record can be leveraged to demonstrate credibility and de-risk partnerships with biotech and pharma clients advancing candidates toward IND/clinical stages.

Global Customer Reach With customers in more than 20 countries across five continents, RetroVirox can offer scalable, geographically distributed testing support and quick mobilization for international partnerships. This can be a compelling selling point for global biotechs seeking consistent virology services across multiple regions.

Flexible Collaboration Models The availability of both fee-for-service and F.T.E. pricing caters to different client needs, from exploratory projects to longer-term collaboration. This flexibility, combined with customized assay development such as drug-resistant strain generation, positions RetroVirox as a partner capable of aligning with varied budgets and project timelines.